Loading
Doing an MRI first and biopsying only suspicious areas found more clinically significant prostate cancers and fewer harmless ones than standard biopsy, while sparing a quarter of men any biopsy at all.
Multicentre randomised non-inferiority trial of 500 biopsy-naive men with suspected prostate cancer randomised to MRI with targeted biopsy of suspicious lesions only (no biopsy if MRI was negative) or standard transrectal ultrasound-guided 10 to 12 core biopsy.
Clinically significant cancer was detected in 38 percent of the MRI group against 26 percent with standard biopsy, clinically insignificant cancer in 9 versus 22 percent, and 28 percent of MRI-group men avoided biopsy.
Pre-biopsy MRI with targeted sampling is now the standard diagnostic pathway for suspected prostate cancer, reducing overdiagnosis of low-risk disease.
The limit of what a prostate scan can be asked to do. It is a good triage test for whether to biopsy and a poor map of where every tumour is, which matters for anyone being offered treatment to part of the gland or follow-up by imaging alone.
The evidence that put a scan in front of the biopsy. It reduces the number of men who are biopsied at all, reduces the number of harmless cancers found, and increases the number of dangerous ones, which is the only combination that improves a screening pathway on both sides at once.
Shares Detection of individual prostate cancer foci via multiparametric magnetic resonance imaging, Template mapping biopsy (transperineal template prostate mapping), PROMIS: diagnostic accuracy of multiparametric MRI and TRUS biopsy in prostate cancer, PI-RADS (Prostate Imaging Reporting and Data System).
Shares Template mapping biopsy (transperineal template prostate mapping), PI-RADS (Prostate Imaging Reporting and Data System), Publish a per-lesion miss rate for every prostate MRI service before it is allowed to guide focal treatment, Prostate cancer roadmap: from Huggins and the discovery that a cancer can depend on a hormone, through the PSA epidemic and what it cost, the androgen receptor drugs, the DNA repair subset and PSMA, to a 2032 registry watch.
Shares PROMIS: diagnostic accuracy of multiparametric MRI and TRUS biopsy in prostate cancer, PI-RADS (Prostate Imaging Reporting and Data System), Prostate cancer roadmap: from Huggins and the discovery that a cancer can depend on a hormone, through the PSA epidemic and what it cost, the androgen receptor drugs, the DNA repair subset and PSMA, to a 2032 registry watch, New England Journal of Medicine.
Shares Publish a per-lesion miss rate for every prostate MRI service before it is allowed to guide focal treatment, Localised prostate cancer, very low and low risk, Prostate cancer roadmap: from Huggins and the discovery that a cancer can depend on a hormone, through the PSA epidemic and what it cost, the androgen receptor drugs, the DNA repair subset and PSMA, to a 2032 registry watch, Prostate cancer.
Shares PI-RADS (Prostate Imaging Reporting and Data System), Publish a per-lesion miss rate for every prostate MRI service before it is allowed to guide focal treatment, Prostate cancer roadmap: from Huggins and the discovery that a cancer can depend on a hormone, through the PSA epidemic and what it cost, the androgen receptor drugs, the DNA repair subset and PSMA, to a 2032 registry watch, Prostate cancer.
Shares PRECISION, Template mapping biopsy (transperineal template prostate mapping), PROMIS: diagnostic accuracy of multiparametric MRI and TRUS biopsy in prostate cancer, PI-RADS (Prostate Imaging Reporting and Data System).
Shares Localised prostate cancer, very low and low risk, Prostate cancer roadmap: from Huggins and the discovery that a cancer can depend on a hormone, through the PSA epidemic and what it cost, the androgen receptor drugs, the DNA repair subset and PSMA, to a 2032 registry watch, New England Journal of Medicine, Prostate cancer.
Shares PRECISION, PROMIS: diagnostic accuracy of multiparametric MRI and TRUS biopsy in prostate cancer, Prostate cancer.